Nanobiotix S.A.
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
NBTX | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 60 RUE DE WATTIGNIES, 75012 PARIS
- Website:
- https://www.nanobiotix.com
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Nanobiotix S.A. is a late-stage clinical biotechnology company pioneering the discovery, development, and commercialization of physics-based nanotherapeutics. The company's lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed for direct injection into solid tumors. When activated by radiotherapy, NBTXR3 locally amplifies the radiation dose within the tumor, aiming to enhance cancer cell destruction without increasing exposure to surrounding healthy tissues. This process is also intended to prime the immune system to attack metastatic cancer cells. Through a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson Company, Nanobiotix is co-developing NBTXR3, initially focusing on cancers of the head, neck, and lungs for patient populations with limited treatment options.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Nanobiotix S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Nanobiotix S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Nanobiotix S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
